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Various studies have documented variation in the management of older patients with breast cancer, 54 
and some of this variation stems from different approaches to balancing the expected benefit of 55 
different treatments, with the ability of patients to tolerate them. Frailty is an emerging concept that 56 
can help to make clinical decisions for older patients more consistent, not least by providing a 57 
measure of ‘biological’ ageing. This would reduce reliance on ‘chronological’ age, which is not a 58 
reliable guide for decisions on the appropriate breast cancer care for older patients.  59 
 60 
This article examines the potential of frailty assessment to inform on breast cancer treatments.  61 
Overall, the current evidence highlights various benefits from implementing comprehensive geriatric 62 
assessment and screening for frailty in breast cancer patients. This includes a role in supporting the 63 
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selection of appropriate therapies and improving physical fitness prior to treatment. However, there 64 
are challenges in implementing routine frailty assessments in a breast cancer service.  Studies have 65 
used a diverse array of frailty assessment instruments, which hampers the generalisability of 66 
research findings. Consequently, a number of issues need to be addressed to clearly establish the 67 
optimal timing of frailty assessment and the role of geriatric medicine specialists in the breast cancer 68 
care pathway.  69 
 70 
203 words  71 
 72 












Clinical guidelines emphasise that breast cancer treatment should be based on clinical need and 81 
patient fitness, rather than age1. For example, the guidelines for early breast cancer issued by the UK 82 
National Institute for Health and Care Excellence (NICE) recommends that women “irrespective of 83 
age, are offered surgery, radiotherapy and appropriate systemic therapy, unless significant 84 
comorbidity precludes it”2. However, various UK-based population level studies report considerable 85 
variation in the breast cancer treatments received by older women (often defined as age 70 years or 86 
older) in comparison to younger women.  87 
 88 
Older women are less likely to receive surgery for operable breast cancer3, 4. Among those older 89 
women who do receive surgery, this is more likely to be a mastectomy than breast conserving 90 
surgery (BCS)5, and of those women having BCS, they are less likely to have adjuvant radiotherapy6, 7. 91 
Older women are also less likely to receive chemotherapy8. There are various possible reasons for 92 
these reported differences in treatment provision. On average, older women tend to have larger 93 
tumours at diagnosis9, which is partly a consequence of being older than the inclusion ages of 94 
women  (usually 50 to 70 years) in national breast screening programmes. The higher burden of 95 
comorbid conditions among older women may also be a significant contributing factor, with various 96 
studies showing lower rates of surgery3 and other therapies10, 11 among women with more comorbid 97 
conditions.  However, these factors only explain some of the reported variation in treatment 98 
patterns between younger and older women. One-third of all breast cancers diagnosed are in 99 
women aged 70 years or over12, so addressing this variation is important for population health .  100 
 101 
The impact of ageing on health is complex and ageing can influence functional ability, physiology and 102 
social wellbeing to different degrees13. Chronological age is increasingly viewed as a poor descriptor 103 
of the ageing process.  More recently, there is a much greater desire to determine “biological age”14, 104 
15.  Geriatric associations have, for a while, recommended that a measure of frailty be used to report 105 
on ageing and its complex sequelae14, 16. This approach has been progressively adopted by other 106 
specialties, perhaps most evidently  in relation to the management of hip fractures17. However, 107 
there has been slow implementation of this recommendation in breast cancer care pathways, not 108 
                                                          
* Abbreviations: BCS – breast conserving surgery, CGA – comprehensive geriatric assessment, EUSOMA – 
European Society of Breast Cancer Specialists, ER – oestrogen receptor, FFF – fit for frailty, NABCOP – National 
Audit of Breast Cancer in Older Patients, PACE – Pre-operative Assessment of Cancer in the Elderly, PET – 




least because it has not proven straightforward to incorporate the assessment of frailty into routine 109 
clinical practice5.   110 
 111 
This article reviews how the identification of frailty in older patients can influence breast cancer 112 
treatment received, and how frailty affects subsequent outcomes.  The article also considers how 113 
frailty assessment might be incorporated into standard practice within breast cancer units and what 114 
challenges need to be overcome to achieve this.  115 
 116 
 117 
What is frailty?  118 
Frailty describes how a person becomes increasingly vulnerable to poor health as a consequence of 119 
an age-related decline in the reserve of multiple physiological systems18. Frailty is closely associated 120 
with comorbidity and disability, but each one constitutes an independent concept of ageing13. Frailty 121 
can also be present without concurrent disability or comorbidity19, and it is not exclusive to a specific 122 
chronological age cut-off20. Consequently, although measures of comorbidity and functional status 123 
are useful in stratifying patients with different clinical needs and health care outcomes21, 22, frailty 124 
adds another dimension in capturing the characteristics of an ageing population23. Specifically, 125 
because frailty is a dynamic manifestation of disease or injury and an increased vulnerability to 126 
stressors, it is potentially reversible with early identification and appropriate interventions24-26.  127 
 128 
There is no single, agreed conceptual model of frailty.  There are currently two dominant concepts:  129 
the ‘phenotype’ model and the ‘cumulative deficit’ model (Appendix 1)19, 27. The ‘phenotype’ model 130 
was developed by Fried et al. and is based on the theory of frailty as a biological syndrome and a 131 
“cycle associated with declining energetics and reserves”19. It is based on five pre-defined physical 132 
frailty elements: weight loss, exhaustion, low physical activity, slowness and weakness. The 133 
classification of a person as: ‘not frail’, ‘pre-frail’ and ‘frail’, is based on their combined performance 134 
in these five elements.  135 
 136 
In the ‘cumulative deficit’ model, frailty is considered as an accumulation of deficits across a number 137 
of domains27. These deficits are related to, but not specific to, the ageing process, and include both 138 
subjective (observed during a clinical examination) and objective (e.g. biochemical tests, presence of 139 
a disease) facets of adverse health and functional status20. This model is the basis for several 140 
objective frailty assessments, with the original frailty index developed for the Canadian Study of 141 
Health and Ageing (CSHA) by Rockwood and colleagues27. The CSHA frailty index consists of 92 142 
6 
 
deficits, with the index expressed as a proportion of the number of deficits present  divided by the 143 
total number possible27. The index threshold for classification of frailty was based on the average 144 
value of individuals with the same chronological age27. Newer frailty indices, such as the Hospital 145 
Frailty Risk Score28, based on the ‘cumulative deficit’ model, have explored the inclusion of further 146 
deficits to measure frailty. It is a feature of this model of frailty, that these newer measures 147 
calculated using different deficits, are still able to identify an increasing burden of frailty among 148 
older people, and demonstrate poorer health outcomes among those who are frail28-30.  149 
 150 
Both concepts of frailty have been successfully operationalised as frailty assessments for use in 151 
populations that include community residents, primary care patients and hospital in-patients. In the 152 
clinical setting, the information on five specific elements of frailty (such as grip strength) provided by 153 
assessments based on the phenotype model are valuable in identifying potentially reversible aspects 154 
of frailty31. In contrast, the individual deficits within a frailty index are not of value by themselves, 155 
and provide little insight into how to clinically respond to health problems at a patient level32. At 156 
population level however, describing frailty as an accumulation of deficits is informative.  Given that 157 
this model is less prescriptive in its construction of frailty, it underpins the majority of the frailty 158 
assessments used in large, primary care29, 30 and administrative hospital datasets28, 33.   159 
 160 
The conceptual basis of frailty and how frailty is best assessed is an ongoing area of research18. This 161 
is necessary to ensure that the operationalisation of these frailty concepts into assessments is 162 
clinically applicable towards the identification and management of frailty in any population. In 163 
parallel, it is equally important to initiate the integration of frailty assessments into clinical practice.  164 
This should be irrespective of disease cohort, with the aim of improving objectivity on the influence 165 
of a patient’s ageing on clinical decisions.  166 
 167 
 168 
Tools for identifying frailty in patients with breast cancer 169 
In the era of multi-modal breast cancer treatment, decisions about a patient’s treatment are made 170 
at various time points throughout their care pathway. In the initial stages, identifying an older 171 
patient’s frailty status can inform clinical decision making, thus guidelines increasingly recommend 172 
the use of formal frailty tools1, 14. Reliance on subjective “end-of-the-bed” opinions of patient frailty 173 
is increasingly undesirable34, especially given the dynamic and potentially reversible nature of frailty. 174 
For example, the perception of frailty in a patient can vary depending on setting (e.g. emergency in-175 




There are a variety of approaches to assessing frailty, and one widely recommended tool by geriatric 178 
professional bodies is the Comprehensive Geriatric Assessment (CGA)14, 35, 36. This provides a “clinical 179 
management strategy which will give a framework for the delivery of interventions which will 180 
address relevant and appropriate issues for an individual patient”16, without prescribing specific 181 
methods for assessing these specific CGA domains (Table 1). However, the CGA typically requires 182 
expertise from a geriatric medicine specialist and has been estimated by Girones et al. to take 183 
between 30 to 40 minutes to complete37.  184 
 185 
The CGA has been used to assess the burden of frailty among breast cancer patients in several 186 
studies, a selection of which are described in Table 2. These frailty assessments were performed for 187 
a range of purposes including the assessment of fitness for primary surgery and the prediction of 188 
adverse treatment outcomes. Irrespective of the purpose of the CGA, patients with increasing age 189 
were more likely to be described as unfit or frail37, 38, and had poorer survival and breast cancer 190 
treatment outcomes38-40.  Two prospective studies evaluated whether routine CGA altered breast 191 
cancer treatment decisions41, 42 and reported different findings. In the study by Okonji et al., women 192 
defined as unfit or frail were less likely to undergo surgery or receive adjuvant chemotherapy42.  In 193 
contrast, Barthélémy et al. reported that the CGA results did not influence MDT decisions on 194 
adjuvant chemotherapy41.  195 
 196 
The variety of study designs in Table 2 also highlight the uncertainty that surrounds the application 197 
of CGA in breast cancer care.  First, there was no consistent definition of ‘old age’, with studies 198 
having inclusion criteria that ranged from patients over 65 to 70 years.  Second, there was 199 
considerable heterogeneity in the patient populations: six studies only included patients with early 200 
breast cancer37, 38, 41, 43, 44 and in two studies, patients with significant cognitive or functional 201 
impairment were specifically excluded40, 42.  Finally, there were discrepancies between the studies in 202 
the types of individual assessments used to assess CGA domains.  This variation might be expected 203 
given that the emphasis of the CGA is on individual domain assessment, with no preference for the 204 
tools used within each domain45.  Nonetheless, this hampers the comparison of results across 205 
studies as well as the ability to extrapolate whether the results can be applied in different settings46. 206 
Overall, these studies illustrate that there is little insight into how CGA results can guide 207 




Undertaking a CGA is labour and time intensive, and there are a range of screening tools available 210 
with the aim of identifying patients who are frail and would benefit from a more comprehensive 211 
assessment47. In the UK, collaborations between professional bodies such as the Fit for frailty† 16, 36 212 
and NHS RightCare Frailty Toolkit‡ 48 clearly distinguishes between tools which screen for and those 213 
that assess frailty. Some of the recommended frailty screening tools include: 214 
• The Program of Research to Integrate Services for the Maintenance of Autonomy (PRISMA)-215 
7 questionnaire49, 216 
• the Clinical Frailty Scale50, 217 
• the Vulnerable Elders Survey (VES-13)51,  218 
• the Edmonton Frail Scale52, and  219 
• the Geriatric 8 (G8) frailty screening tool53.  220 
Neither Fit for Frailty, nor NHS RightCare, advocate one specific screening tool due to concerns that 221 
certain instruments may have good sensitivity but poor specificity in identifying frailty, and the 222 
accuracy of individual tools depend on the population assessed54. In contrast, the International 223 
Society of Geriatric Oncology (SIOG) declares a preference for the G8 tool for the identification of 224 
frailty in older cancer patients47. However, only a few of the aforementioned frailty screening tools 225 
(i.e. VES-1351, Fried criteria55, 56, G853, 57) have been used for patients with breast cancer, thus the 226 
utility of other tools are unclear. 227 
 228 
There are several other dominant reasons for why there is no current consensus on the most 229 
appropriate frailty screening tool for use in patients with breast cancer. These are highlighted in 230 
several systematic reviews of frailty assessment tools in general use. De Vries et al. identified and 231 
reviewed 20 different frailty assessment tools58. Although there was some consistency in the factors 232 
that were included in most of the frailty assessments: physical activity, mobility, strength, energy, 233 
nutritional status, cognition, mood, and social relations, there was wide heterogeneity between 234 
tools58. Aguayo et al. reviewed the agreement in the rating of frailty among 35 tools and only noted 235 
moderate agreement in the classification of people as frail46. Despite the conclusion of these reviews 236 
and a lack of consensus on frailty tools, there is an ever-growing number of studies addressing the 237 
value of frailty identification in older patients, at various stages of the breast cancer care pathway.  238 
 239 
 240 
                                                          
†
 Fit for frailty is a collaborative between British Society of Geriatrics, Age UK and Royal College of General 
Practitioners 
‡
 NHS RightCare Frailty Toolkit was developed in collaboration with NHS England’s National Clinical Director for 
Older People, Age UK, Getting It Right First Time (GIRFT) and NICE 
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Frailty and surgical treatment planning in early breast cancer 241 
Surgery is the standard of care for patients with early invasive breast cancer, unless significant 242 
burden of poor fitness precludes it1, 2. Elective breast surgery carries a comparably low risk of 243 
mortality, and the impact of chronological age and comorbidity burden on post-operative 244 
complications is negligible59, 60. Specifically, it is only in the presence of poor functional status and 245 
cognitive impairment that multiple comorbidities is associated with post-operative mortality and 246 
functional decline61. Despite this, studies repeatedly report a lower rate of surgical resection for 247 
older patients with breast cancer, based on age and comorbidity profile3, 4. This is particularly the 248 
case in patients with oestrogen receptor (ER-) positive disease for which primary endocrine therapy 249 
(PET) is available as an ‘alternative’ treatment5, despite the inferiority of PET on disease-free 250 
survival62.  251 
 252 
The Pre-operative Assessment of Cancer in the Elderly (PACE) was developed to measure the 253 
functional reserve of older cancer patients with the aim of “reducing unacceptable denial of 254 
potentially curative surgery”63. PACE incorporates the CGA and surgical risk assessments. Early 255 
results from the PACE study provide insight on how information from a multi-domain frailty 256 
assessment may influence surgical treatment decisions and short term post-operative outcomes63. 257 
For example, patients with poor scores had higher rates of 30-day surgical complications60. However, 258 
only 47% (of the 460 patients) in the study cohort had breast cancer, and the results were not 259 
reported by cancer type. This limits the extrapolation of PACE to guide surgical decisions for patients 260 
with breast cancer.  261 
 262 
There are advocates for omitting extensive axillary surgery for older patients with early stage 263 
invasive breast cancer, to minimise morbidity without compromising oncological outcomes. Large 264 
longitudinal population-based studies have shown that this perspective is increasingly adopted, with 265 
fewer older patients undergoing comprehensive axillary staging over time64. Whether frailty 266 
assessments can provide information to guide decisions on axillary management independent of 267 
decisions on primary breast surgery for older patients, is unclear. Few studies specifically address 268 
this question, though a multi-centre prospective study using the CGA reported that frailty was not 269 
strongly associated with non-receipt of axillary surgery among women who were having primary 270 




Frailty and primary endocrine therapy 273 
The evidence base on how formal frailty assessments in older patients with breast cancer might 274 
contribute towards the decision between PET and surgical treatment, or how frailty is associated 275 
with breast cancer outcomes among patients taking PET, is lacking1.  In addition, the majority of 276 
studies addressing treatment selection mainly examined the association between PET, or surgery, 277 
and comorbidity4, 65. One exception is the ongoing ‘Bridging the Age Gap Study’ which examines the 278 
use a clinical decision support tool specifically for older patients with breast cancer66.  Long-term 279 
follow-up results for this study are still outstanding.  280 
 281 
The SIOG and European Society of Breast Cancer Specialists (EUSOMA) recommend PET for patients 282 
with ER-positive disease who have “poor predicted life expectancy or who are unfit for surgery after 283 
medical optimisation”67. Framing the decision in relation to life expectancy highlights the potential 284 
role for frailty assessment to complement the assessment of fitness for surgical treatment. 285 
Identification of frailty creates an opportunity to provide interventions that may improve a patient’s 286 
frailty status, either before or after primary treatment. Given that a higher burden of frailty, 287 
irrespective of method of frailty assessment, is associated with shorter life expectancy, optimisation 288 
of frailty components has the potential value of improving disease-specific and overall survival. 289 
Frailty assessments are also applicable in optimising patients for palliative surgical resections with a 290 
view to minimising symptoms or disease progression on PET68.  291 
 292 
Frailty and adjuvant therapies in breast cancer: Chemotherapy 293 
In contrast to younger patients with breast cancer, the evidence base to support chemotherapy 294 
decisions in older age patients is limited. Older patients are often poorly represented in clinical 295 
trials69, 70, and several large international multi-centre randomised trials aimed at addressing 296 
treatment in the older cohort were terminated prematurely due to insufficient accrual71, 72,. 297 
Consequently, much of the available evidence stems from population-level studies that demonstrate 298 
an association between adjuvant chemotherapy and survival benefits in older patients with high-risk 299 
tumour characteristics (such as axillary nodal metastasis)11, 73. However, it is not possible to confirm 300 
causality from observational studies. 301 
 302 
Guidelines emphasise that the decision to offer chemotherapy to older patients with breast cancer 303 
should not be based on age67. However, older age is associated with higher rates of chemotherapy 304 
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related toxicity and mortality70, 74 and chronological age is perceived as an important patient 305 
characteristic by oncologists when considering adjuvant chemotherapy75. Few published population 306 
level studies account for patient characteristics beyond chronological age and comorbidity, and this 307 
has likely contributed to the lower uptake of adjuvant chemotherapy among older patients11, 70, 76.   308 
 309 
There is increasing support for the use of frailty assessments to identify patients who are at 310 
increased risk of chemotherapy toxicity, or who require additional support to facilitate completion of 311 
regimes77, 78. For example, in a pilot study by Extermann et al., fifteen patients underwent a CGA 312 
assessment prior to and during adjuvant chemotherapy. Issues identified by the CGA led to a range 313 
of medical, nutritional and psychological interventions that directly influenced the care of four out of 314 
the fifteen patients43. Allowing for the small sample size, the study highlights the range of issues that 315 
can be identified and addressed by a formal frailty assessment. In another study, Kalsi et al. 316 
evaluated whether a frailty assessment could improve chemotherapy tolerance in patients with 317 
various types of cancer. The process led to an average of six interventions per patient before or 318 
during the course of systemic therapy. There was also improved tolerance to treatment regimens in 319 
comparison to a control group. Collectively, these studies illustrate the value of a multidisciplinary 320 
team approach in managing selected older patients with breast cancer, with a particular role for a 321 
specialist geriatrician in the consideration for, and delivery of, chemotherapy.  322 
 323 
Frailty and adjuvant therapies in breast cancer: Radiotherapy 324 
The use of radiotherapy in older patients with breast cancer mirrors that observed for 325 
chemotherapy, with lower levels of radiotherapy uptake in older age6, 79. This might be similarly due 326 
to the lack of evidence on long-term survival benefit after radiotherapy in this cohort80-82. Several 327 
randomised-trials have reported no increased risk of complications from radiotherapy with older 328 
age80, 83. However, radiotherapy was delivered in the adjuvant setting (after surgery) in these studies, 329 
and frail patients are less likely to receive surgery. Therefore, it is unclear how these reports of 330 
minimal radiotherapy complications in a cohort of fit older patients can be applied to a frail cohort. 331 
There are some smaller studies examining the association between frailty and radiotherapy toxicity 332 
in older (non-breast) cancer patients84, 85. However, these studies were inconsistent in their findings 333 




It is not understood whether frailty assessments can support the delivery of radiotherapy in older 336 
patients with breast cancer86, though some small studies have suggested potential utility. For 337 
example, Denkinger et al. suggested that the CGA was superior to other assessments of patient 338 
characteristics in predicting fatigue after radiotherapy87. In addition, because CGA covers multiple 339 
frailty domains88, it also has the potential to capture issues related to transport and travel for 340 
treatment - logistical factors known to influence radiotherapy uptake89.  341 
 342 
Challenges in the implementation of frailty assessments in breast cancer 343 
In the UK, there has been slow uptake towards the implementation of frailty assessments as part of 344 
routine clinical practice for breast cancer5, 90. As examined, one reason for this could be the lack of a 345 
strong evidence base, both in terms of the effects of the frailty assessment process and the types 346 
and range of interventions that should be employed. However, reassuringly, this is being addressed 347 
with an increasing number of studies investigating the value of frailty assessments throughout the 348 
breast cancer patient pathway.  349 
 350 
Another reason might be the lack of capacity within geriatric services to provide support for frailty 351 
assessments of cancer patients. It is more realistic that breast cancer services would need to adopt a 352 
screening process to identify patients who would benefit from a more extensive frailty assessment, 353 
in order to minimise the requirement for specialist input. However, even if sufficient expertise can 354 
be provided, the next challenge is to identify a consistent method of screening or fully assessing 355 
frailty, and the ‘ideal’ point in a patient care pathway to apply this.  356 
 357 
Prior to implementing a frailty assessment into the service pathway for breast cancer care, it is 358 
important to be clear on the purpose of identifying frailty in a patient. If the aim of the frailty 359 
assessment is to inform on the risk of complications from breast cancer treatments for each patient, 360 
the focus of the assessment and interventions could be rationalised to focus on those frailty 361 
domains (within the CGA) that are strongly associated with treatment-related morbidity and 362 
survival. However, if the purpose of the frailty assessment is to evaluate the overall health of the 363 
patient with a view to optimising their fitness for breast cancer treatments, then all the frailty 364 




Finally, there are also several key issues to address in an effort to strengthen the current evidence 367 
base.  368 
 369 
• There needs to be consistency in the assessment of frailty in older patients with breast 370 
cancer. 371 
Consensus statements and guidelines should include an aim to have a position on the preferred 372 
types of frailty screening and assessment tools. This should include more precise recommendations, 373 
than currently exist, concerning the appropriate tools for the various frailty domains, as described by 374 
the CGA, and how the results might link to interventions for optimising patients for cancer 375 
treatments (e.g. the involvement of onco-geriatric specialities).  Improving the consistency in 376 
reporting standards will enable more robust comparisons between studies and provide valuable 377 
information on patient outcomes. It will also improve the quality of studies evaluating the 378 
implementation of frailty assessments in breast cancer care pathways. Applied at a population level, 379 
a standardised method of reporting on frailty will also enhance the understanding of how patient 380 
factors contribute to national variations and differences in patterns of treatment for breast cancer 381 
between age cohorts. 382 
 383 
• The role of the frailty assessment needs to be clearly defined in the breast cancer patient 384 
pathway 385 
While studies have begun to illustrate how information about patient frailty can influence treatment 386 
decisions for older patients, there is little understanding of how frailty screening or assessment are 387 
best utilised along the breast cancer care pathways of different  patient  groups91. A multi-faceted 388 
assessment can identify and optimise health deficits for cancer treatment and individualise patient 389 
management (including both early stage and advanced disease). Clear practical advice is required to 390 
ensure that the results of frailty assessments are used as a guide to inform treatment decisions, and 391 
not as a checklist or ‘hurdle to overcome’ in accessing particular cancer treatments.   392 
 393 
• The role of  geriatric medicine in the breast cancer care pathway needs to be defined 394 
In the UK, few breast cancer units work in collaboration with geriatric services in their management 395 
of older patients9. A small number of studies have shown that geriatric services can make a valuable 396 
contribution towards planning and delivery of cancer therapy39, 60, 78, 92.  A pragmatic compromise in 397 
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most units could be a standardised screening process to identify patients who are frail and who 398 
would benefit from onward referral for specialist geriatric input.  399 
 400 
In summary, a formal assessment of frailty in the breast cancer care pathway has the potential to 401 
improve objectivity in management decisions and identify underlying health problems in older 402 
patients that can be optimised to improve the chances of successful treatment. Heterogeneity in the 403 
available methods for screening and assessing frailty is an important challenge to overcome for 404 
implementation into clinical practice. However, it is also important to be clear on the reason for 405 
frailty assessments in the treatment pathway, and the role of the geriatric specialist in facilitating a 406 
holistic approach to breast cancer care. 407 
 408 
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 410 
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Table 1: Frailty domains assessed in the Comprehensive Geriatric Assessment (CGA) 670 
 671 
Multi-dimensional CGA assessment components: 
• Physical symptoms 
• Mental health symptoms 
• Level of function in daily activity: for personal care and life activities 
• Social support network (formal e.g. carers and informal e.g. family and 
friends)  
• Living environment (including ability to use local facilities and 
technological support) 
• Level of participation and individual concerns 
• Compensatory mechanisms and resourcefulness which is used by the 




Table 2: A summary of studies using the comprehensive geriatric assessment (CGA) on breast cancer patients 673 
 674 
Abbreviations: ADL – Activities of Daily Living, ASA – American Society of Anaesthesiology, BMI – Body Mass Index, CCI – Charlson Comorbidity Index, Cumulative illness 675 
Rating Scale for Geriatrics (CIRS-G), ECOG PS –Eastern Cooperative Oncology Group performance status, ER – oestrogen receptor, GDS – Geriatric Depression Scale,  iADL – 676 






Study objective Number of 
patients, age 










(Jan 2012 – Oct 2015) 
 
Stage I – III breast 
cancer, aged ≥70 years 
with no severe 
cognitive impairment  
To use CGA to 








Comorbidity: CCI, clinical interview 
Cognition: 6-Cognitive Impairment Test (6-CIT) 
Functional status: ADL, iADL 
 
Other: ASA grade, ECOG PS 
Frailty screening tools: Vulnerable Elder Survey 
(VES-13), G8 
 
Definition of fit: 
ECOG PS ≤ 1, ASA grade ≤ II, 6-CIT ≤ 7, VES-
13 ≤ 2, ADL ≥ 6, IADL ≥ 8, G8 ≥15 and CCI ≤ 
1. 
 
Older patients were reported as less ‘fit’ 
(35% in 70 – 74 years, 61% in 75 – 84 
years, 12% in ≥ 85 years) 
 
In comparison to fit patients, unfit patients 
were less likely to undergo primary breast 
cancer resection (100% vs. 91%, p = 0.002) 
and receive adjuvant chemotherapy (51% 
vs. 20%, p=0001). 
 
Patient fitness, independent of age, did 
not affect the proportion of patients 
undergoing axillary surgery, receiving 
radiotherapy after wide local excision, 
Trastuzumab (in HER2-positive patients 









retrospective study  
(Jan 2005 – May 2012) 
 
Women with primary 
early ER-positive 
breast cancer where 
there were concerns 
regarding fitness to 
receive standard 
treatment 
The use of CGA to 
predict 3-year 




82 years  
(range: 43 – 
98 years) 
Comorbidity: Satariano score/CCI 
Cognition: MMSE 
Mental Health: GDS 
Functional status: Barthel Index of ADL, IADL 
 
Other: ASA score  
212/328 (65%) had surgical treatment 
after CGA assessment.  
 
97% of the cohort had died by 3 years. 
 
Comorbidity, MMSE, poor functional 
status and ASA grade was associated with 
3-year mortality.  
 
CGA was predictive of 3-year survival 
probability (ROC of the survival model = 








trial (Dutch Breast 
Cancer Trialists’ Group 
OMEGA study) (Apr 
2007 – Sept 2011) 
 
Metastatic breast 
cancer patient, aged 
≥65 years, good ECOG 
PS (0-2) and good 
health status 
To evaluate the 
use of CGA/ 





















Mental health: GDS 
Functional status: iADL 
Number of medications used  




Cut-off scores for deficiencies/ impairment 
CCI ≥2, IADL: partial dependence 14–27; full 
functional dependence ≤13, polypharmacy ≥5, 
undernutrition = ≤20 kg/m
2
, MMSE ≤23, GDS: 
severe depressive symptoms ≥10, moderate 
depressive symptoms 5–9.  
 
Classification of frailty 
≥1 of full IADL dependence, comorbidity score 
≥2, polypharmacy, cognitive impairment, 
undernutrition and/or moderate to severe 
depressive symptoms 
 
Study terminated early due to poor 
accrual  
 
There was no difference in chemotherapy 
toxicity rates between the two arms of the 
study. 
 
Increasing number of CGA deficiencies was 
associated with grade 3-4 chemotherapy-
related toxicity. Polypharmacy was the 
only individual factor within the CGA that 
was associated with toxicity.  
 
54/78 (69%) of patients died (median 
follow-up 32 months). 
 
Median survival between fit (19.9 months) 
vs. frail (10.3 months, p = 0.04) became 
non-significant when adjusting for age, PS 











Women with stage I-II 
operable primary 










Mean age 80 
years (max 
92 years) 
Mental health: Hospital Anxiety and Depression 
Scale (HADS), Blessed Orientation-Memory-
Concentration test (BOMC) 
Functional status: iADL, ADL, Karnofsky self-
reported performance rating scale, TUG test 
Geriatric syndromes: falls, polypharmacy 
Self-reported health: Older American Resources 
and Services (OARS) 
Nutrition: self-reported weight loss, BMI 
Social support: MOS Social Support Survey, 
Seeman and Berkman Social Ties 
62% of the cohort had surgical treatment 
 
Increasing age, polypharmacy, greater 
comorbidity and slow TUG test results 
were associated with a reduced likelihood 
of receiving surgery.  
 
No difference in quality of life score (at 6 
weeks or at 6 months) between those who 












Women with stage I 
(tumour size >1cm) or 
II-IIIa breast cancer, 
aged ≥65 years; 




on cancer specific 
CGA domains in 







Using cancer-specific geriatric assessment  
(C-SGA) consisting of 4 main domains. 
 
Clinical: CCI, BMI 
Psychosocial: Mental Health Index (MHI5), 
medical outcomes study social support scale 
(MOS-SSS) 
Self-rated health status 
Socio-demographic: adequate financial 
resources 
 
Women with ≥3 C-CGA deficits had poorer 
5 and 10-year all cause (HR 1.87, 1.74) and 









(July 2006 – July 2009) 
 
Patients with primary 
early breast cancer, 
age 70 – 79 years (with 
one comorbidity) and 
all patients >79 years  
 











75 years  
(range: 70 – 
98 years) 
Comorbidity: CIRS-G 
Cognitive function: MMSE 
Mental health: GDS 
Functional status: iADL, ADL, ECOG PS  
Geriatric syndromes: falls 
Nutritional status: BMI, MNA 
 
Classification 
Fit = no deficiencies in the domains above 
Frail = >1 major deficiency 
 
Patient age and tumour characteristics 
were associated with MDT 
recommendations for adjuvant 
characteristics 
 
Patient CGA results were not associated 













(Jan 2005 – June 2006) 
 
Patients treated for 
early primary breast 
cancer, aged ≥70 years 
















Mean age at 
surgery = 76 
years (range: 
70 – 92 
years) 
 
Mean age at 
CGA = 80 
years 




Mental health: GDS 
Functional status: iADL, ADL, ECOG PS 
Geriatric Syndromes: dementia, delirium, 
depression, falls, neglect and abuse, 
spontaneous bone fractures 
Nutrition: MNA 
Pharmacy: number and appropriateness of 
medications, risk of drug interactions 




CGA was performed at follow-up visit. The 
median interval between diagnosis and CGA 
was 39 months (range 2 – 120 months).  
 
Inclusion criteria was biased towards 
patients with good cognitive function.  
 
Study found low prevalence of functional 
limitations (4%) and cognitive impairment 
(16%). Hypertension and peripheral 
vascular disease were the most common 
comorbidities. Presence of comorbidity 
was independent of functional limitations 
and age.  
 
High number of prescribed medications 
(75% on > 6 medications). 
 






Patients treated with 
surgery for stage I – II 
breast cancer, aged ≥ 
70 years; prior to 


















(range: 72 – 
87 years) 
Quality of life – Functional Assessment of 
Cancer Treatment- Breast (FACT-B) 
Functional status – iADL, ADL, ECOG PS 
Mental health – GDS 
Cognitive function – MMSE 
Nutrition – MNA 
Comorbidity – CCI, CIRS-G  
 
Regular 3 monthly assessments during follow-
up period, after surgical treatment. 
CGA identified problems throughout their 
cancer care, with opportunities for 
preventative interventions.  
 
The cancer care of 4/11 patients directly 







Appendix 1: A comparison of the variables included in the phenotype and cumulative deficit models 683 






Fried et al19 
Cumulative deficit model  
Mitniski et al27 (26) 
Cognition / Mood  Delirium, Sleep changes, Memory problems, 
Mood problems, Sadness 
Nutritional problems Baseline:>10lbs lost unintentionally in 
prior year 
(Shrinking: unintentional weight loss), 
sarcopenia (loss of muscle mass) 
Gastrointestinal symptoms 
Sensory problems  Hearing or visual problems 
Energy / Activity levels  Self-reported exhaustion 
Poor endurance: exhaustion 
Kcals /week: lowest 20% 




weakness: Grip strength - score 1 if 
lowest 20% (by gender, body mass 
index) 
slowness: Walking time/.15 feet: 
slowest 20% (by gender, height) 
Mobility impairment, Gait abnormality,  
Difficulty in going out / cooking / getting 
dressed / grooming/ bathing/ toileting, Tremor 
(resting/ action), Dyskinesia’s/ chorea, 




 Urinary/stool incontinence, Urinary symptoms 
Medical co-morbidities    History of thyroid disease, Diabetes Mellitus,  
Clinical abnormalities in head / neck / 
neurology  thyroid/ breast/ lungs/ 
cardiovascular/ peripheral pulses/ abdomen/ 
rectum/ skin examination, Biochemical 
abnormalities of Sodium / Potassium / Urea / 
Creatinine/ Calcium / Phosphate / Thyroid 
stimulating hormone / vitamin B12 / Folate / 
vDRL / protein / albumin levels, Renal 
disease, Parkinson’s disease, Hypertension, 
Cardiac symptoms, Cardiovascular disease, 
Cerebrovascular disease 
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